Filter

Refine by collections

Refine by date

—
  • Print
  • Save

Search Results

You are looking at 1 - 10 of 25 items for :

  • cabergoline x
Clear All
Hélène Lasolle Fédération d’Endocrinologie, Centre de Référence Maladies Rares Hypophysaires HYPO, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
Faculté de Médecine Lyon Est, Université Lyon 1, Lyon, France
INSERM U1052; CNRS UMR5286; Cancer Research Centre of Lyon, Lyon, France

Search for other papers by Hélène Lasolle in
Google Scholar
PubMed Close
,
Amandine Ferriere Service d’endocrinologie, diabète et nutrition, Hôpital Haut Lévêque, CHU de Bordeaux, Bordeaux, France
UFR Sciences médicales, Université de Bordeaux, Bordeaux, France

Search for other papers by Amandine Ferriere in
Google Scholar
PubMed Close
,
Alexandre Vasiljevic Faculté de Médecine Lyon Est, Université Lyon 1, Lyon, France
INSERM U1052; CNRS UMR5286; Cancer Research Centre of Lyon, Lyon, France
Centre de Pathologie et de Neuropathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France

Search for other papers by Alexandre Vasiljevic in
Google Scholar
PubMed Close
,
Sandrine Eimer UFR Sciences médicales, Université de Bordeaux, Bordeaux, France
Service d’anatomo-pathologie, Hopital Pellegrin, CHU de Bordeaux, Bordeaux, France

Search for other papers by Sandrine Eimer in
Google Scholar
PubMed Close
,
Marie-Laure Nunes Service d’endocrinologie, diabète et nutrition, Hôpital Haut Lévêque, CHU de Bordeaux, Bordeaux, France

Search for other papers by Marie-Laure Nunes in
Google Scholar
PubMed Close
, and
Antoine Tabarin Service d’endocrinologie, diabète et nutrition, Hôpital Haut Lévêque, CHU de Bordeaux, Bordeaux, France
UFR Sciences médicales, Université de Bordeaux, Bordeaux, France

Search for other papers by Antoine Tabarin in
Google Scholar
PubMed Close

, pegvisomant (PEG), is a second-line treatment which normalizes IGF-1 plasma levels in 60–70% ( 5 ) of patients in follow-up registries and up to 97% in single-center series ( 6 ). The dopamine D2-receptor agonist, cabergoline, is an alternative to 1 GSSA

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-19-0332
Volume/Issue:
Volume 8: Issue 10
Open access
Shruti Khare Department of Endocrinology, Seth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India

Search for other papers by Shruti Khare in
Google Scholar
PubMed Close
,
Anurag R Lila Department of Endocrinology, Seth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India

Search for other papers by Anurag R Lila in
Google Scholar
PubMed Close
,
Hiren Patt Department of Endocrinology, Seth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India

Search for other papers by Hiren Patt in
Google Scholar
PubMed Close
,
Chaitanya Yerawar Department of Endocrinology, Seth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India

Search for other papers by Chaitanya Yerawar in
Google Scholar
PubMed Close
,
Manjunath Goroshi Department of Endocrinology, Seth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India

Search for other papers by Manjunath Goroshi in
Google Scholar
PubMed Close
,
Tushar Bandgar Department of Endocrinology, Seth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India

Search for other papers by Tushar Bandgar in
Google Scholar
PubMed Close
, and
Nalini S Shah Department of Endocrinology, Seth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India

Search for other papers by Nalini S Shah in
Google Scholar
PubMed Close

cabergoline is the first line therapy for macroprolactinoma. Cabergoline is started at dose of 0.25 mg in the first week and then increased to 0.5 mg/week in the second week. Further dose is escalated (if need be) by 1 mg/week, at 2 monthly intervals. Before

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-15-0105
Volume/Issue:
Volume 5: Issue 1
Open access
Anastasia P Athanasoulia-Kaspar Max Planck Institute of Psychiatry, Department of Internal Medicine, Endocrinology and Clinical Chemistry, Munich, Germany

Search for other papers by Anastasia P Athanasoulia-Kaspar in
Google Scholar
PubMed Close
,
Kathrin H Popp Max Planck Institute of Psychiatry, Department of Internal Medicine, Endocrinology and Clinical Chemistry, Munich, Germany

Search for other papers by Kathrin H Popp in
Google Scholar
PubMed Close
, and
Gunter Karl Stalla Max Planck Institute of Psychiatry, Department of Internal Medicine, Endocrinology and Clinical Chemistry, Munich, Germany

Search for other papers by Gunter Karl Stalla in
Google Scholar
PubMed Close

.09.1998–01.03.1999; 24.06.1999–03.12.2001) with interruptions and in combination with cabergoline (02.10.1998–07.10.1999; 03.12.2001-ongoing). Interestingly, the psychiatric symptoms were similar under all dopamine agonists administered with the ICD codes including

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-18-0030
Volume/Issue:
Volume 7: Issue 2
Open access
Nelma Veronica Marques Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Search for other papers by Nelma Veronica Marques in
Google Scholar
PubMed Close
,
Luiz Eduardo Armondi Wildemberg Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Search for other papers by Luiz Eduardo Armondi Wildemberg in
Google Scholar
PubMed Close
, and
Monica R Gadelha Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Search for other papers by Monica R Gadelha in
Google Scholar
PubMed Close

≥ 126 mg/dL, glycated haemoglobin (HbA1c) ≥ 6.5% or receiving medication for hyperglycaemia. Nine patients had undergone transsphenoidal surgery before pasireotide treatment. Most patients had been treated with first-generation SRLs and/or cabergoline

Article Type:
Research Article
Collections:
Pituitary and Hypothalamus
DOI:
https://doi.org/10.1530/EC-23-0155
Volume/Issue:
Volume 12: Issue 10
Open access
Lijin Ji Division of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

Search for other papers by Lijin Ji in
Google Scholar
PubMed Close
,
Na Yi Division of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

Search for other papers by Na Yi in
Google Scholar
PubMed Close
,
Qi Zhang Division of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

Search for other papers by Qi Zhang in
Google Scholar
PubMed Close
,
Shuo Zhang Division of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

Search for other papers by Shuo Zhang in
Google Scholar
PubMed Close
,
Xiaoxia Liu Division of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

Search for other papers by Xiaoxia Liu in
Google Scholar
PubMed Close
,
Hongli Shi Division of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

Search for other papers by Hongli Shi in
Google Scholar
PubMed Close
, and
Bin Lu Division of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

Search for other papers by Bin Lu in
Google Scholar
PubMed Close

effects. Tumor mass effects can cause visual field defects, decreased vision, headaches and can even be life threatening. Drug therapy is recommended for prolactinoma, and the dopamine receptor agonists (DAs) bromocriptine and cabergoline are commonly

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-18-0250
Volume/Issue:
Volume 7: Issue 10
Open access
Sarah Byberg Department of Medical Endocrinology, Copenhagen University Hospital, Copenhagen, Denmark

Search for other papers by Sarah Byberg in
Google Scholar
PubMed Close
,
Jesper Futtrup Panum Institute, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Jesper Futtrup in
Google Scholar
PubMed Close
,
Mikkel Andreassen Department of Medical Endocrinology, Copenhagen University Hospital, Copenhagen, Denmark

Search for other papers by Mikkel Andreassen in
Google Scholar
PubMed Close
, and
Jesper Krogh Department of Medical Endocrinology, Copenhagen University Hospital, Copenhagen, Denmark

Search for other papers by Jesper Krogh in
Google Scholar
PubMed Close

hyperprolactinemia OR prolactinoma) AND (dopamine agonist OR dostinex OR cabergoline OR bromocriptine). The search was restricted to titles. One investigator (SB) conducted the main search. Based on title and abstract, obviously irrelevant titles were removed and

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-19-0286
Volume/Issue:
Volume 8: Issue 10
Open access
Julie M Silverstein Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8127, St Louis, Missouri 63110, USA

Search for other papers by Julie M Silverstein in
Google Scholar
PubMed Close

-acting dopamine agonists such as carbergoline (1) . Cabergoline is recommended in patients with mild disease, defined as IGF1 levels less than two times the upper limit of normal, and in cases of co-secretion with prolactin (1, 15) . In clinical studies, ∼30% of

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-15-0064
Volume/Issue:
Volume 4: Issue 4
Open access
Bernardo Maia Neuroendocrinology Research Center/Endocrinology Division – Medical School and Hospital Universitário Clementino Fraga Filho – Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Search for other papers by Bernardo Maia in
Google Scholar
PubMed Close
,
Leandro Kasuki Neuroendocrinology Research Center/Endocrinology Division – Medical School and Hospital Universitário Clementino Fraga Filho – Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
Neuroendocrinology Division – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Endocrinology Division – Hospital Federal de Bonsucesso, Rio de Janeiro Brazil

Search for other papers by Leandro Kasuki in
Google Scholar
PubMed Close
, and
Mônica R Gadelha Neuroendocrinology Research Center/Endocrinology Division – Medical School and Hospital Universitário Clementino Fraga Filho – Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
Neuroendocrinology Division – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Neuropatology and Molecular Genetics Laboratory – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil

Search for other papers by Mônica R Gadelha in
Google Scholar
PubMed Close

, gastrointestinal, injection-site reactions Cabergoline (4, 22, 26) Dopamine receptor agonist 1.5–3.5 mg/week, PO (by mouth) 18 Tumor shrinkage (33%) Gastrointestinal, nasal congestion, fatigue, orthostasis, headache, cardiac valve abnormalities

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-20-0433
Volume/Issue:
Volume 9: Issue 12
Open access
G Giuffrida Endocrine Unit of University Hospital ‘AOU Policlinico G. Martino’, Messina, Italy
PhD School of Clinical and Experimental Biomedical Sciences, University of Messina, Messina, Sicily, Italy

Search for other papers by G Giuffrida in
Google Scholar
PubMed Close
,
F Ferraù Endocrine Unit of University Hospital ‘AOU Policlinico G. Martino’, Messina, Italy
Department of Human Pathology ‘G. Barresi’, University of Messina, Messina, Sicily, Italy

Search for other papers by F Ferraù in
Google Scholar
PubMed Close
,
R Laudicella Nuclear Medicine Unit of University Hospital ‘AOU Policlinico G. Martino’, Messina, Italy
Department of Biomorphology, University of Messina, Messina, Sicily, Italy

Search for other papers by R Laudicella in
Google Scholar
PubMed Close
,
O R Cotta Department of Human Pathology ‘G. Barresi’, University of Messina, Messina, Sicily, Italy

Search for other papers by O R Cotta in
Google Scholar
PubMed Close
,
E Messina Endocrine Unit of University Hospital ‘AOU Policlinico G. Martino’, Messina, Italy

Search for other papers by E Messina in
Google Scholar
PubMed Close
,
F Granata Department of Biomorphology, University of Messina, Messina, Sicily, Italy
Neuroradiology Unit of University Hospital ‘AOU Policlinico G. Martino’, Messina, Italy

Search for other papers by F Granata in
Google Scholar
PubMed Close
,
F F Angileri Department of Biomorphology, University of Messina, Messina, Sicily, Italy
Neurosurgery Unit of University Hospital ‘AOU Policlinico G. Martino’, Messina, Italy

Search for other papers by F F Angileri in
Google Scholar
PubMed Close
,
A Vento Nuclear Medicine Unit of University Hospital ‘AOU Policlinico G. Martino’, Messina, Italy
Department of Biomorphology, University of Messina, Messina, Sicily, Italy

Search for other papers by A Vento in
Google Scholar
PubMed Close
,
A Alibrandi Department of Economics, University of Messina, Messina, Sicily, Italy

Search for other papers by A Alibrandi in
Google Scholar
PubMed Close
,
S Baldari Nuclear Medicine Unit of University Hospital ‘AOU Policlinico G. Martino’, Messina, Italy
Department of Biomorphology, University of Messina, Messina, Sicily, Italy

Search for other papers by S Baldari in
Google Scholar
PubMed Close
, and
S Cannavò Endocrine Unit of University Hospital ‘AOU Policlinico G. Martino’, Messina, Italy
PhD School of Clinical and Experimental Biomedical Sciences, University of Messina, Messina, Sicily, Italy
Department of Human Pathology ‘G. Barresi’, University of Messina, Messina, Sicily, Italy

Search for other papers by S Cannavò in
Google Scholar
PubMed Close

In this patient, macroprolactinoma was diagnosed when she was 42 years old and trans-sphenoidal surgery was performed after few months of ineffective high-dose cabergoline treatment. At the age of 55 years, serum PRL concentrations remarkably

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-19-0065
Volume/Issue:
Volume 8: Issue 5
Open access
Mikkel Andreassen Department of Endocrinology, Faculty of Health Science, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Mikkel Andreassen in
Google Scholar
PubMed Close
,
Anders Juul Department of Growth and Reproduction, Faculty of Health Science, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Anders Juul in
Google Scholar
PubMed Close
,
Ulla Feldt-Rasmussen Department of Endocrinology, Faculty of Health Science, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed Close
, and
Niels Jørgensen Department of Growth and Reproduction, Faculty of Health Science, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Niels Jørgensen in
Google Scholar
PubMed Close

– 2037 . ( https://doi.org/10.1093/humrep/dev158 ) 10.1093/humrep/dev158 8 De Rosa M Colao A Di SA Ferone D Landi ML Zarrilli S Paesano L Merola B Lombardi G. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-18-0061
Volume/Issue:
Volume 7: Issue 4
Open access